Should Hims & Hers Stock's Drop After Earnings Worry You?

Hims & Hers Health (HIMS) stock dropped 16.6% after reporting Q3 2026 earnings. Revenue of $890M missed estimates by 2.2%, and EPS was -$0.10 vs. expected $0.06 profit. Subscribers fell by 100,000 to 2.8M. Management cut full-year EBITDA and revenue forecasts, citing marketing adjustments and delayed revenue recognition.

Original reporting
Published Nov 13, 2026, 8:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Should Hims & Hers Stock's Drop After Earnings Worry You? — source image
Decision brief

The 30-second read

$HIMSBearishHigh
01

Why it matters

The earnings miss triggered a 16.6% intraday decline, highlighting execution risk in its weight‑loss segment.

02

Market read

The earnings surprise is the primary driver of the stock move and may influence peer valuations in the telehealth space.

03

What to watch

Free cash flow turned positive and international growth remains strong, which could mitigate the downside.

Relevance 8/10Novelty 8/10Timing: after‑hours reaction

Background

Hims & Hers Health reported Q3 2026 results after market close, missing revenue and EPS expectations and cutting full‑year EBITDA guidance.

Company-level read

Ticker impact

$HIMSBearishHigh confidence
Context

Q3 2026 earnings miss and guidance cut caused a 16.6% share drop.

Expected impact

likely further downside as market prices in weaker revenue and margin outlook

Evidence & confidence

Revenue fell short of estimates, EPS missed, margins compressed and guidance lowered, driving the sharp sell‑off.

Market effects

Weight‑loss and telehealth subsectors may see broader scrutiny after the miss.

U.S. small‑cap health tech stocks could face short‑term pressure.

Limited to investors tracking U.S. health‑tech earnings.

Counterpoint

The stock may be oversold; upcoming product launches could spark a rebound.

Key entities

  • Hims & Hers Health

    U.S. telehealth and consumer wellness provider.

Related articles

$HIMSMed

Canaccord reiterates Hims & Hers stock rating on peptide launch

Canaccord Genuity reiterated a Buy rating and $40 price target for Hims & Hers Health (HIMS) after its launch of Peptides+ treatment line. The company reported Q3 revenue of $890M, up 49% YoY, but saw a subscriber decline. Analysts have mixed views on its outlook, with some lowering price targets due to subscriber losses and others optimistic about future growth.

$HIMSMed

Wisconsin joins federal lawsuit against Hims & Hers telehealth provider

Wisconsin joined a federal lawsuit against Hims & Hers Health, alleging the telehealth provider shared customer health data with Meta and Snapchat, and engaged in deceptive subscription practices. The state seeks an injunction and restitution. Hims denies wrongdoing, stating it provides clear information to customers. The FTC and six other states are also involved.

$HIMSHighAI 8/10

Hims & Hers Revenue Climbs 49% as Gross Margin Falls to 57%

Hims & Hers reported Q3 2026 revenue of $890.4M, up 49% YoY, but gross margin fell to 57% from 74%. Net loss was $33M vs. $15.8M net income a year ago. Adjusted EBITDA rose to $82.4M. The company forecasts Q4 revenue of $875M-$895M and full-year revenue of $3.13B-$3.15B, but lowered adjusted EBITDA guidance to $257M-$277M.